Tom3 schreef op 1 april 2024 14:33:
2 wijzigingen van adviezen door analisten:
Affimed price target raised to $10 from $5 at H.C.
Wainwright H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Affimed to $10 from $5 and keeps a Buy rating on the shares. The analyst says AFM24 could be an attractive target for a partnership. Positive data could position AFM24 as a viable therapy for the treatment of epidermal growth factor receptor non-small-cell lung cancer patients, the analyst tells investors in a research note.
Affimed price target lowered to $25 from $30 at
Wells Fargo Wells Fargo lowered the firm's price target on Affimed to $25 from $30 and keeps an Overweight rating on the shares. Following review of company Q4 2023 update, the firm remains optimistic that the Phase 2 LuminICE-203 study of AFM13 + AB-101 can meet the bar set by KOLs.